Opinion|Videos|January 2, 2025
Emerging Data for Odronextamab in DLBCL
Panelists discuss how emerging data on odronextamab in diffuse large B-cell lymphoma suggest its potential to play a significant role in therapy, with promising results that may position it alongside or as a superior option compared with currently approved bispecifics.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What do the emerging data on odronextamab in diffuse large B-cell lymphoma suggest about its future role in therapy, and how does it compare to currently approved bispecifics?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Unexplained Pauses Hit Nearly Half of Monthly-Updated CDC Databases, Raising Transparency Concerns
2
Clinical Trial Data Signal a New Era for Atopic Dermatitis, Melanoma, and Psoriasis
3
CRC Becomes Leading Cause of Cancer-Related Death in Younger Adults, Highlighting Prevention Gaps
4
ACE Inhibitors Linked to Reduced Mortality in Patients with Idiopathic Pulmonary Fibrosis
5
